Kingmed Diagnostics was among the investors in the $44.7m round, the proceeds of which will fund development of Creative Biosciences' cancer diagnostics kits.
China-based cancer testing kit provider Creative Biosciences raised RMB300m ($44.7m) on Friday in a series B round that included two funds affiliated with medical testing services provider Kingmed Diagnostics.
The round was co-led by venture capital group IDG Capital and private equity firm CDH Investments, and also featured fellow private equity firm CD Capital.
Founded in 2015, Creative Biosciences develops and sells cancer diagnostics kits and equipment. The company’s flagship product, Colosafe, is used to detect colorectal cancer, which is…
